Pharmacokinetics of Temocapril and Enalapril in Patients with Various Degrees of Renal Insufficiency

Temocapril is a novel ACE inhibitor that is cleared via dual excretion routes in humans. Borderline or mildly hypertensive patients with normal renal function [group 1, creatinine clearance (CLcr) >70 ml/min (4.2 L/h), n = 12], moderate renal impairment [group 2, CLcr 30 to 70 ml/min (1.8 to 4.2 L/h), n = 12] or severe renal impairment [group 3, CLcr <30 ml/min (1.8 L/h), n = 12] received a single oral dose of either temocapril 1mg (n = 6, each group) or enalapril 5mg (n = 6, each group).